Cardinal Health Q4 Earnings Beat Estimates Despite Revenue Miss

Cardinal Health (CAH) reported fourth-quarter fiscal 2026 adjusted earnings per share of $2.91, surpassing the Zacks Consensus Estimate by 20.3%. This result drove a 40% year-over-year increase in the bottom line, supported by higher operating earnings, IEEPA tariff refunds, a lower tax rate, and a reduced share count. GAAP earnings per share for the quarter stood at $1.70, compared with $1.00 in the year-ago period. Despite the earnings beat, the company's total revenues of $63.67 billion, up 6% year over year, missed the consensus estimate by 2.9%.

For the full fiscal year 2026, Cardinal Health recorded adjusted EPS of $11.26, a 37% increase from the prior year, while GAAP EPS rose to $7.23 from $6.45. Total annual revenues reached $254.25 billion, marking a 14% year-over-year growth. The company’s cash position strengthened to $4.86 billion at the end of the quarter, up from $3.94 billion in the previous quarter, with net cash from operating activities totaling $5.17 billion, nearly double the year-ago figure of $2.39 billion.

Segment Performance Drives Profit Growth

The Pharmaceutical and Specialty Solutions segment was the primary driver of profitability, with revenues increasing 6% to $58.85 billion on growth in brand and specialty pharmaceutical sales. Segment profit rose 21% to $645 million, aided by positive generics program performance. Conversely, the Global Medical Products and Distribution segment saw revenues decline 2% to $3.13 billion due to lower distribution volumes and the recognition of expected IEEPA tariff refund repayments. However, segment profit more than doubled to $150 million from $70 million, primarily driven by the IEEPA tariff refunds.

The 'Other' segment, comprising Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics, reported revenues of $1.72 billion, up 7% year over year. Profit in this group increased 14% to $183 million, fueled by growth in OptiFreight Logistics and at-Home Solutions. Overall, gross profit increased 16% to $2.56 billion, with gross margin expanding by approximately 36 basis points to 4.0% of revenues. Operating income surged 70% year over year to $729 million, while adjusted operating income rose 30% to $935 million.

Fiscal 2027 Guidance Excludes Tariff Benefits

Cardinal Health has provided fiscal 2027 guidance, projecting adjusted EPS in the range of $12.40 to $12.60. This implies growth of 13% to 15% from fiscal 2026 adjusted results, excluding the benefit of IEEPA tariff refunds. The company expects revenues from the Pharmaceutical and Specialty Solutions segment to grow between 3% and 5% year over year, with segmental profit projected to increase by 8% to 11%. These targets reflect a strategic focus on sustainable organic growth rather than one-time regulatory impacts.

Market Reaction and Financial Context

Shares of Cardinal Health have added approximately 2.5% since the last earnings report, outperforming the S&P 500 during the same period. According to GN markets/earnings (en-US), the positive trend may continue or face a pullback depending on how investors weigh the revenue miss against the significant earnings beat. The company’s improved cash flow and margin expansion provide a solid financial foundation, though the reliance on tariff refunds in the current period necessitates careful evaluation of future organic growth drivers.